Advertisement

Natalizumab

  • Giuseppe TridenteEmail author
Chapter

Abstract

Natalizumab (Tysabri®, Elan, Biogen) is a recombinant humanized IgG4 murine antibody binding to α4β1 and α4β7 integrins. In November 2004, FDA granted approval for treatment of relapsing forms of multiple sclerosis (MS). However, as soon as February 2005 the Agency suspended the marketing due to two cases of progressive multifocal leukoencephalopathy (PML) in MS-treated patients, but readmitted the biomedicine in 2006 with a mandatory restriction of participation to a RiskMAP (TOUCH) distribution program, to assess and minimize the risk of PML and other serious AEs. During 2006, EMEA examined the requests for approval in MS and in Crohn’s disease (CD), and granted approval for rapidly evolving severe relapsing-remitting MS and for highly active relapsing-remitting MS resistant to IFNβ, but rejected the CD indication, which was re-examined in 2008 with confirmed refusal. In 2006, Health Canada approved natalizumab for treatment of MS in patients with inadequate response or intolerance to other therapies for that disease. The Japanese PMDA approved natalizumab in MS patients in 2008.

Keywords

Multiple Sclerosis Multiple Sclerosis Patient Progressive Multifocal Leukoencephalopathy Glatiramer Acetate Immune Reconstitution Inflammatory Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

307171_1_En_27_MOESM1_ESM.xls (92 kb)
Supplementary material 1 (XLS 91.5 kb)

References

  1. 1.
    Natalizumab (Tysabri®) BLA 125104 Medical Review, FDA Nov 2004Google Scholar
  2. 2.
    Natalizumab (Tysabri®) WC 500070715 Refusal CHMP Assessment Report, EMEA Nov 2007Google Scholar
  3. 3.
    Natalizumab (Tysabri®) WC 500095872 Assessment Report, EMEA May 2010Google Scholar
  4. 4.
    Natalizumab (Tysabri®) WC500044686 EPAR Product Information Annex I, EMEA Jan 2012Google Scholar
  5. 5.
    Natalizumab (Tysabri®) SBD 093001 Health Canada, Oct 2005Google Scholar
  6. 6.
    Natalizumab (Tysabri®) for Crohn’s Disease (CD) Briefing Book, Biogen June 2007Google Scholar
  7. 7.
    Natalizumab (Tysabri®) Product Information, Elan Jan 2012Google Scholar
  8. 8.
    Stangel M, Kieseier BC (2010) Pharmacotherapy options for multiple sclerosis: focus on natalizumab. Clin Med Insights Ther 2:947–952CrossRefGoogle Scholar
  9. 9.
    Selewski DT, Shah GV, Segal BM et al. (2010) Natalizumab (Tysabri). AJNR. doi  10.3174/ajnr.A2226
  10. 10.
    Bielekova B, Becker BL (2010) Monoclonal antibodies in MS. Neurology 74:S31–S40PubMedCrossRefGoogle Scholar
  11. 11.
    Hutchinson M (2007) Natalizumab: a new treatment for relapsing remitting multiple sclerosis. Therap Clin Risk Manag 3:259–268CrossRefGoogle Scholar
  12. 12.
    Bloomgren G, Richman S, Hotermans C et al (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. NEJM 366:1870–1880PubMedCrossRefGoogle Scholar
  13. 13.
    Ferenczy MW, Marshall LJ, Nelson CDS et al (2012) Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 25:471–506PubMedCrossRefGoogle Scholar
  14. 14.
    Tan IL, McArthur JC, Clifford DB et al (2010) Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77:1061–1067CrossRefGoogle Scholar
  15. 15.
    Metz I, Radue E-W, Oterino A et al (2012) Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol 123:235–245PubMedCrossRefGoogle Scholar
  16. 16.
    Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J et al (2012) Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol 71:604–617PubMedCrossRefGoogle Scholar
  17. 17.
    Goodman AD, Rossman H, Bar-Or A et al (2009) GLANCE results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 72:806–812PubMedCrossRefGoogle Scholar
  18. 18.
    Pellegrini F, Belachew S, Butzkueven H et al. (2012) Long-term safety and efficacy of natalizumab and assessment of 2-year freedom from clinical disease activity in patients with multiple sclerosis in the Tysabri® observational programme. In: ECTRIMS 28th Congress Lyon, 10–12 October (abstract)Google Scholar
  19. 19.
    Bomprezzi R, Okuda DT, Alderazi YJ et al (2012) From injection therapies to natalizumab: views on the treatment of multiple sclerosis. Ther Adv Neurol Disord 5:97–104PubMedCrossRefGoogle Scholar
  20. 20.
    Hyams JS, Wilson DC, Thomas A et al (2007) Natalizumab therapy for moderate to severe Crohn’s disease in adolescents. J Ped Gestroenterol Nutr 44:185–191CrossRefGoogle Scholar
  21. 21.
    Kane SV, Horst S, Sandborn WJ et al (2012) Natalizumab for moderate to severe Crohn’s disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis 18:2203–2208PubMedCrossRefGoogle Scholar
  22. 22.
    Juillerat P, Wasan SK, Fowler S et al. (2012) Efficacy and safety of natalizumab in Crohn’s disease patients treated at six academic Boston hospitals. In: ECCO VII Annual Congress Barcelona, February 2012, abstract P297Google Scholar
  23. 23.
    Parisinos CA, Lees CW, Wallace WAH et al (2011) Sarcoidosis complicating treatment with natalizumab for Crohn’s disease. Thorax 66:1109–1110PubMedCrossRefGoogle Scholar
  24. 24.
    Gouldthorpe O, Gatto-Smith AG, Alex G (2007) Biologics in paediatric Crohn’s disease. Gastroenterol Res Pract. doi: 10.1155/2011/287574 Google Scholar
  25. 25.
    Kachuck NJ (2005) Challenges and opportunities: what we are learning from the clinical natalizumab experience. Expert Rev Neurother 5:605–615PubMedCrossRefGoogle Scholar
  26. 26.
    Johnston BL, Conly MD (2006) Alemtuzumab and natalizumab: the monoclonal antibody story continues. Can J Infect Dis Med Microbiol 17:327–329PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations